dacarbazine

/deuh kahr"beuh zeen'/, n. Pharm.
a toxic, light-sensitive powder, C6H10N6O, used in the treatment of Hodgkin's disease and metastatic malignant melanoma.
[1960-65; contr. and rearrangement of the chemical name]

* * *


Universalium. 2010.

Look at other dictionaries:

  • Dacarbazine — Systematic (IUPAC) name 5 (3,3 Dimethyl 1 triazenyl)imidazole 4 carboxamide Clinical data Trade names D …   Wikipedia

  • Dacarbazine — Général Nom IUPAC 5 (3,3 diméthyl 1 triazényl)imidazole 4 carboxamide No CAS …   Wikipédia en Français

  • dacarbazine — noun An antineoplastic drug used in chemotherapy …   Wiktionary

  • dacarbazine — An antineoplastic agent used in the treatment of malignant melanoma and sarcoma. * * * da·car·ba·zine də kär bə .zēn n an antineoplastic agent C6H10N6O used to treat esp. metastatic malignant melanoma, tumors of adult soft tissue, and Hodgkin s… …   Medical dictionary

  • dacarbazine — n. a drug administered by injection in the treatment of melanoma and (in combination with other cytotoxic drugs) certain other cancers, including Hodgkin s disease. Side effects include severe vomiting. Trade names: DTIC Dome …   The new mediacal dictionary

  • dacarbazine — An anticancer drug that is a type of alkylating agent …   English dictionary of cancer terms

  • dacarbazine — /deuh kahr beuh zeen /, n. Pharm. a toxic, light sensitive powder, C6H10N6O, used in the treatment of Hodgkin s disease and metastatic malignant melanoma. [1960 65; contr. and rearrangement of the chemical name] …   Useful english dictionary

  • 4342-03-4 — Dacarbazine Dacarbazine Général Nom IUPAC 5 (3,3 diméthyl 1 triazényl)imidazole 4 carboxamide N …   Wikipédia en Français

  • DTIC — • dacarbazine; • dimethyltriazenyl imidazole carboxamide …   Dictionary of medical acronyms & abbreviations

  • Melanoma — Classification and external resources A melanoma ICD 10 C43 …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.